News

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...
The promise of a new era of cholesterol management, heralded by the launch of highly effective PCSK9 inhibitors, has been complicated by significant barriers to uptake of the next-generation products ...
Anti-PCSK9 antibodies are the jewel in the crown of modern genomic medicine, illustrating what many hope will be a paradigm for future drug discovery.
For whichever PCSK9 we choose, we get an additional 50% to 60% LDL reduction by using these therapies. So, they work. They lower events. Both trials with PCSK9 inhibitors lowered events by about 15%.
MedCo. is a one-drug company whose lead asset, inclisiran, is one of several injectable, cholesterol-lowering meds known as PCSK9 inhibitors. And that’s a drug class with a checkered past. The two ...
PCSK9’s story begins a dozen years ago when researchers led by Nabil G. Seidah of the Clinical Research Institute of Montreal discovered an unusual protein (Proc. Natl. Acad. Sci. USA 2003, DOI ...
The PCSK9 inhibitors pose a similar, but in many ways more compelling and complex, set of problems. Their target, hyperlipidemia, is one of the most prevalent conditions in the developed world.
PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies Petra El Khoury Sandy Elbitar Marianne Abifadel Current Atherosclerosis Reports (2017) ...
A large case-control study using genetic proxies for PCSK9 inhibitors may help alleviate concerns that the dyslipidemia agents could promote adverse cardiac remodeling and heart failure.
Compared with placebo, PCSK9 inhibition carried a lower rate of death or intubation in the first 30 days (23.3% vs 53.3%), with numerical reductions in both of the individual components of that ...
Investigators have been able to successfully use RNA interference to block the production of PCSK9, a protein that regulates LDL-receptor protein levels and function, and lower cholesterol levels ...